Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
종목 코드 CAI
회사 이름Caris Life Sciences Inc
상장일Jun 18, 2025
CEOMr. David Dean Halbert
직원 수- -
유형Ordinary Share
회계 연도 종료Jun 18
주소750 West John Carpenter Freeway
도시IRVING
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호75039
전화18667718946
웹사이트https://www.carislifesciences.com/
종목 코드 CAI
상장일Jun 18, 2025
CEOMr. David Dean Halbert
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음